Trump Justice Department Seeks Dismissal of Mifepristone Case on Standing, Venue Grounds
The Trump Justice Department on May 5, 2025, asked a federal judge to dismiss or transfer a lawsuit brought by Idaho, Kansas and Missouri that seeks to restrict telehealth access to mifepristone, the abortion medication at the center of a long-running national fight. In its filing, the government did not argue the merits of whether mifepristone should remain widely available. It said the states had not shown standing and that the case should be heard in a district where venue is proper. ([apnews.com](https://apnews.com/article/e5a89a12e98fc4c529d487daba81606a?utm_source=openai))
That is a procedural position, not an endorsement of abortion policy. But it does have a practical effect: it pushes back against an effort by three Republican-led states to use this case to cut off a distribution method that has become central to medication abortion. The government’s lawyers said the claims before that court should be dismissed or transferred under the venue statute’s mandatory command. ([apnews.com](https://apnews.com/article/e5a89a12e98fc4c529d487daba81606a?utm_source=openai))
The filing keeps the dispute in motion without resolving the larger fight over mifepristone. The drug remains a major target for abortion opponents, and telehealth and mail delivery have become key parts of how it is obtained in the United States. The Justice Department’s move leaves those access questions for another day and another court, while the immediate fight stays on the narrower question of who can sue, and where. ([apnews.com](https://apnews.com/article/e5a89a12e98fc4c529d487daba81606a?utm_source=openai))
The case also fits a familiar pattern in abortion litigation: the outcome often turns less on broad declarations than on standing, venue and other threshold rules. That matters because procedural defeats can stall a challenge even when the political pressure behind it remains intense. On this filing, the administration chose the courthouse gatekeeping fight instead of a merits defense of the drug itself. ([apnews.com](https://apnews.com/article/e5a89a12e98fc4c529d487daba81606a?utm_source=openai))
Comments
Threaded replies, voting, and reports are live. New users still go through screening on their first approved comments.
Log in to comment
No comments yet. Be the first reasonably on-topic person here.